Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma (Q34495684)

2 August 2017

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma (English)

1 reference

2 August 2017

2

Bernard Escudier

1 reference

2 August 2017

18

Philip W Kantoff

1 reference

2 August 2017

1

Toni K Choueiri

1 reference

ORCID Public Data File 2021

2 August 2017

1 reference

Bhumsuk Keam

14

object named as

Bhumsuk Keam

1 reference

2 August 2017

Thomas Powles

3

1 reference

2 August 2017

Paul N Mainwaring

4

1 reference

2 August 2017

Brian I Rini

5

1 reference

2 August 2017

Frede Donskov

6

1 reference

2 August 2017

Hans Hammers

7

1 reference

2 August 2017

Thomas E Hutson

8

1 reference

2 August 2017

Jae-Lyun Lee

9

1 reference

2 August 2017

Katriina Peltola

10

1 reference

2 August 2017

Bruce J Roth

11

1 reference

2 August 2017

Georg A Bjarnason

12

1 reference

2 August 2017

Lajos Géczi

13

1 reference

2 August 2017

Pablo Maroto

15

1 reference

2 August 2017

Daniel Y C Heng

16

1 reference

2 August 2017

Manuela Schmidinger

17

1 reference

2 August 2017

Anne Borgman-Hagey

19

1 reference

2 August 2017

Colin Hessel

20

1 reference

2 August 2017

Christian Scheffold

21

1 reference

2 August 2017

Gisela M Schwab

22

1 reference

2 August 2017

Nizar M Tannir

23

1 reference

2 August 2017

Robert J Motzer

24

1 reference

2 August 2017

METEOR Investigators

25

1 reference

2 August 2017

language of work or name

English

0 references

publication date

25 September 2015

1 reference

The New England Journal of Medicine

2 August 2017

1 reference

2 August 2017

373

1 reference

2 August 2017

19

1 reference

2 August 2017

1814-1823

1 reference

Sequencing systemic therapies for metastatic kidney cancer

2 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

The VHL/HIF axis in clear cell renal carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5024539

6 July 2018

Identifiers

DOI

10.1056/NEJMOA1510016

1 reference

2 August 2017

1 reference

2 August 2017

1 reference